Menu Search
Equities

Clinical Laserthermia Systems AB

LS60:DEU

Clinical Laserthermia Systems AB

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Clinical Laserthermia Systems AB is a Sweden-based company active in the medical equipment industry. The Company develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). imILT method can be used for all tumors in solid organ and the potential market is considerable. Examples of tumors which are suitable for treatment are those found in liver, breast, lung, prostate, kidney, pancreas and thyroid. Clinical Laserthermia Systems AB's treatment system consists of two main parts: a mobile laser device and a sterile patient unit for single use. The Company's product is intended for medical professionals within surgical oncology or interventional radiology within oncology. In April 2014, the Company announced the establishment of a subsidiary in the United States.

  • Revenue in SEK (TTM)18.63m
  • Net income in SEK-64.20m
  • Incorporated2006
  • Employees7.00
  • Location
    Clinical Laserthermia Systems ABScheelev. 2, building 405LUND 223 81SwedenSWE
  • Phone+46 46152100
  • Websitehttps://clinicallaser.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.